Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IBI 363

Next Previous
X
Search
Drug Profile

IBI 363

Alternative Names: IBI-363

Latest Information Update: 08 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovent Biologics
  • Class Antibodies; Antineoplastics; Cytokines; Immunotherapies; Interleukins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 2 expression stimulants; Interleukin 2 replacements; Programmed cell death 1 receptor antagonists; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Malignant melanoma
  • Phase I Lymphoma
  • Clinical Phase Unknown Cancer

Most Recent Events

  • 30 Sep 2024 Shanghai plans a phase II trial for Non small cell lung cancer in China in September 2024 (NCT06620822)
  • 24 Sep 2024 Zhejiang Cancer Hospital plans a phase I trial for Gastric cancer and Adenocarcinoma (Metastatic disease, Late-stage disease) in September 2024 (NCT06610799)
  • 18 Sep 2024 Efficacy and adverse event data from a phase Ib trial in Colorectal cancer released by Innovent Biologics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top